Biotium Launches New Line of Extensively Validated Primary Antibody Conjugates for Flow Cytometry

Biotium, a leading provider of innovative solutions for life science research, is thrilled to announce the launch of Biotium Choice primary antibody conjugates. With careful curation, and extensive in-house validation, Biotium Choice monoclonal primary antibodies are designed to deliver exceptional performance for flow cytometry.

Biotium Choice antibody conjugates are available in a selection of CF® Dyes, Astral™ Leap tandem dyes, and PE. CF® Dyes are Biotium's unique fluorescent probes that offer exceptional brightness and signal-to-noise. Astral Leap™ tandem dyes are Biotium‘s new long Stokes shift dyes for enhanced multiplexing in flow cytometry. Featuring breakthrough chemical strategies to optimize both the Förster Resonance Energy Transfer (FRET) dye capabilities and conjugation to the fluorescent protein, Astral Leap™ tandem dyes provide expanded multiplexing options and exceptional signal-to-noise compared to other commercially available tandem dyes. RPE-Astral™616 and APC-Astral™813 are currently available for select Biotium Choice antibody conjugates with more tandem dyes on the way.

Biotium Choice primary antibody conjugates are currently available in several widely published clones against common targets including CD3e, CD4, CD8a, CD9, CD16, CD19, CD45, CD63, and CD81. Biotium intends to expand the catalog significantly with more targets, label options, and validated applications.

Key features of Biotium Choice primary antibody conjugates

  • Widely published clones against common targets
  • Developed and optimized for flow cytometry
  • Available with bright CF® Dyes, Astral™ tandem dyes, PE, and more
  • New antibody clones and conjugate options on the way

The release of the Biotium Choice primary antibodies adds to Biotium’s growing catalog of robust and validated probes for life science research.

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Biotium, Inc.. (2023, December 06). Biotium Launches New Line of Extensively Validated Primary Antibody Conjugates for Flow Cytometry. AZoLifeSciences. Retrieved on July 19, 2024 from https://www.azolifesciences.com/news/20231206/Biotium-Launches-New-Line-of-Extensively-Validated-Primary-Antibody-Conjugates-for-Flow-Cytometry.aspx.

  • MLA

    Biotium, Inc.. "Biotium Launches New Line of Extensively Validated Primary Antibody Conjugates for Flow Cytometry". AZoLifeSciences. 19 July 2024. <https://www.azolifesciences.com/news/20231206/Biotium-Launches-New-Line-of-Extensively-Validated-Primary-Antibody-Conjugates-for-Flow-Cytometry.aspx>.

  • Chicago

    Biotium, Inc.. "Biotium Launches New Line of Extensively Validated Primary Antibody Conjugates for Flow Cytometry". AZoLifeSciences. https://www.azolifesciences.com/news/20231206/Biotium-Launches-New-Line-of-Extensively-Validated-Primary-Antibody-Conjugates-for-Flow-Cytometry.aspx. (accessed July 19, 2024).

  • Harvard

    Biotium, Inc.. 2023. Biotium Launches New Line of Extensively Validated Primary Antibody Conjugates for Flow Cytometry. AZoLifeSciences, viewed 19 July 2024, https://www.azolifesciences.com/news/20231206/Biotium-Launches-New-Line-of-Extensively-Validated-Primary-Antibody-Conjugates-for-Flow-Cytometry.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.